Reducing the Сardiotoxicity of Daunorubicin by Conjugation with Natural Sesquiterpene Lactones
https://doi.org/10.33647/2074-5982-20-3-37-46
Abstract
We present the results of a histological study into the cardiotoxicity of conjugates of daunorubicin with dehydrocostus lactone and epoxyisoalantolactone in mature male mice of the C57BL/6 line. The effect of conjugates on the morphology of cardiomyocytes and the structure of the left ventricular myocardium in mice was studied.
Supporting agencies: the study was supported by the budget of the IPAC RAS State Target-2024 (topic No. FFSG- 2024-0021). Conjugates of daunorubicin with sesquiterpene lactones were synthesized within the framework of the Russian Science Foundation project No. 19-73-00343. Acknowledgments: the authors express their gratitude to the Center for Preclinical Tests of the Institute of Physiologically Active Compounds of the Russian Academy of Sciences for providing histological equipment for the preparation and analysis of histological preparations of the heart.
About the Authors
A. A. Globa
Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
Russian Federation
Russian Federation
Anastasiya A. Globa
142432, Moscow Region, Chernogolovka, Severny Passage, 1
A. V. Semakov
Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
Russian Federation
Russian Federation
Aleksey V. Semakov
142432, Moscow Region, Chernogolovka, Severny Passage, 1
S. A. Pukhov
Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
Russian Federation
Russian Federation
Sergey A. Pukhov, Cand. Sci. (Chem.)
142432, Moscow Region, Chernogolovka, Severny Passage, 1
S. V. Afanasyeva
Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
Russian Federation
Russian Federation
Svetlana V. Afanasyeva, Cand. Sci. (Chem.)
142432, Moscow Region, Chernogolovka, Severny Passage, 1
L. V. Anikina
Institute of Physiologically Active Compounds, Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry of the Russian Academy of Sciences
Russian Federation
Russian Federation
Lada V. Anikina, Cand. Sci. (Biol.)
142432, Moscow Region, Chernogolovka, Severny Passage, 1
References
1. Avtandilov G.G. Medicinskaya morfometriya. Rukovodstvo [Medical morphometry. Guide]. Moscow: Medicina Publ., 1990:384 (In Russian)].
2. Archakova L.I., Novakovskaya S.A. Kletochnye mexanizmy antraciklinovoj kardiomiopatii pri dejstvii antibiotika doksorubicina [Cell mechanisms of antracycline cardiomyopathy under antibiotic doxorubicin treatment]. Izvestiya Natsional'noy akademii nauk Belarusi. Seriya meditsinskikh nauk [Proceedings of the National Academy of Sciences of Belarus, Medical series]. 2017;(1):83–89 (In Russian)].
3. Gendlin G.E., Emelina E.I., Nikitin I.G., Vasyuk Yu.A. Sovremennyy vzglyad na kardiotoksichnost' khimioterapii onkologicheskikh zabolevaniy, vklyuchayushchey antratsiklinovye antibiotiki [Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines]. Rossiyskiy kardiologicheskiy zhurnal [Russian Journal of Cardiology]. 2017;(3):145–154. (In Russian)]. DOI: 10.15829/1560-4071-2017-3-145-154
4. Matyas M.G., Kravchuk T.L., Vysotskaya V.V. Inducirovannaya antraciklinami kardiotoksichnost`: mexanizmy razvitiya i klinicheskie proyavleniya [Anthracycline-induced cardiotoxicity: Mechanisms of development and clinical manifestations]. Sibirskiy onkologicheskiy zhurnal [Siberian journal of oncology]. 2008;6(30):66–75. (In Russian)].
5. Muzhikyan A.A., Makarova M.N., Gushchin Ya.A. Osobennosti gistologicheskoj obrabotki organov i tkanej laboratornyh zhivotnyh [Features of histological processing of organs and tissues of laboratory animals]. Mezhdunarodnyy vestnik veterinarii [International Bulletin of Veterinary Medicine]. 2014;(2):103-109. (In Russian)].
6. Nepomnyashchikh L.M. Morfogenez vazhneyshikh obshchepatologicheskikh protsessov v serdtse [Morphogenesis of the most important general pathological processes in the heart]. Novosibirsk: Nauka Publ., 1991:352. (In Russian)].
7. Bovelli D., Plataniotis G., Roila F.; ESMO Guidelines Working Group. Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Ann. Oncol. 2010;21(Suppl. 5):277–282. DOI: 10.1093/annonc/mdq200
8. Couture L., Nash J.A., Turgeon J. The ATP-binding cassette transporters and their implication in drug disposition: A special look at the heart. Pharmacol. Rev. 2006;58(2):244–258. DOI: 10.1124/pr.58.2.7
9. de Baat E.C., Mulder R.L., Armenian S., Feijen E.A., Grotenhuis H., Hudson M.M. Mavinkurve-Groothuis A.M.C., Kremer L.C.M., van Dalen E.C. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst. Rev. 2022;9(9):CD014638. DOI: 10.1002/14651858.CD014638.pub2
10. European convention for the protection of vertebrate animals used for experimental and other scientific purposes. European Treaty Series. 1986:123.
11. Hasinoff B.B., Patel D., Wu X. The role of topoisomerase IIβ in the mechanisms of action of the doxorubicin cardioprotective agent dexrazoxane. Cardiovasc. Toxicol. 2020;20(3):312–320. DOI: 10.1007/s12012-019-09554-5
12. Kourek C., Touloupaki M., Rempakos A., Loritis K., Tsougkos E., Paraskevaidis I., Briasoulis A. Cardioprotective strategies from cardiotoxicity in cancer patients: A comprehensive review. J. Cardiovasc. Dev. Dis. 2022;9(8):259. DOI: 10.3390/jcdd9080259
13. Pukhov S.A., Semakov A.V., Globa A.A., Anikina L.V., Afanasyeva S.V., Yandulova E.Y., Aleksandrova Y.R., Neganova M.E., Klochkov S.G. New conjugates of daunorubicin with sesquiterpene lactones and their biological activity. Chemistry Select. 2021;32(6):8446–8451. DOI: 10.1002/slct.202102244
14. Semakov A.V., Anikina L.V., Pukhov S.A., Afanas`eva S.V., Klochkov S.G. Conjugates of alan-tolactone with anthracycline antibiotics. Chem. Nat. Compd. 2016;52(4):695–696. DOI: 10.1007/s10600-016-1744-y
15. Swain S.M., Whaley F.S., Gerber M.C., Weisberg S., York M., Spicer D., Jones S.E., Wadler S., Desai A., Vogel C., Speyer J., Mittelman A., Reddy S., Pendergrass K., Velez-Garcia E., Ewer M.S., Bianchine J.R., Gams R.A. Cardioprotection with dexrazoxane for doxorubicincontaining therapy in advanced breast cancer. J. Clin. Oncol. 1997;15(4):1318–1332. DOI: 10.1200/JCO.1997.15.4.1318
Review
For citations:
Globa A.A., Semakov A.V., Pukhov S.A., Afanasyeva S.V., Anikina L.V. Reducing the Сardiotoxicity of Daunorubicin by Conjugation with Natural Sesquiterpene Lactones. Journal Biomed. 2024;20(3):37-46. (In Russ.) https://doi.org/10.33647/2074-5982-20-3-37-46
Views:
77
Email this article 
